logo

For the Inventor, By the Inventor

Research Triangle Park, NC, United States of America

G1 Therapeutics, Inc.


USPTO Granted Patents = 48



Trademarks = 6

Forward Citations = 576

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal Jay Copeland Strum (41 out of 53 patents)

silverMedal Francis Xavier Tavares (28 out of 47 patents)

bronzeMedal Patrick Joseph Roberts (18 out of 24 patents)

4.  John Emerson Bisi (18 out of 23 patents)

5.  Hannah S White (7 out of 12 patents)

6.  Jessica A Sorrentino (5 out of 7 patents)

7.  Alexander Smith (5 out of 16 patents)

8.  Robert C Gadwood (3 out of 34 patents)

9.  Ricky D Gaston (3 out of 3 patents)

10.  Stephen E Schneider (3 out of 9 patents)

11.  Andrew Beelen (2 out of 3 patents)

12.  Jaroslaw Mazurek (2 out of 4 patents)

13.  Sergiy Krasutsky (2 out of 4 patents)

14.  Jian-Xie Chen (2 out of 2 patents)

15.  Roberta L Dorrow (2 out of 2 patents)


Core Competencies:
Trilaciclib
G1T38
Chemotherapy
CDK Inhibitors
HSPC-Sparing Treatments
Anti-Neoplastic Combinations
Pyrimidine-Based Compounds
Transient Protection
Topoisomerase Inhibitors
Cancer Treatment
Benzothiophene Modulators
Lactam Kinase Inhibitors

48 patents:

1. 12168666 - Morphic forms of trilaciclib and methods of manufacture thereof (2024-12-17),
2. 12139494 - Morphic forms of G1T38 and methods of manufacture thereof (2024-11-12),
3. 11717523 - Transient protection of normal cells during chemotherapy (2023-08-08),
4. 11708337 - Synthesis of 1,4-diazaspiro[5.5]undecan-3-one (2023-07-25),
5. 11654148 - HSPC-sparing treatments for RB-positive abnormal cellular proliferation (2023-05-23),
6. 11643416 - Substituted 1',2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors (2023-05-09),
7. 11629150 - Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines (2023-04-18),
8. 11529352 - Preservation of immune response during chemotherapy regimens (2022-12-20),
9. 11446295 - Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors (2022-09-20),
10. 11395821 - Treatment of EGFR-driven cancer with fewer side effects (2022-07-26),
11. 11364222 - Combination therapy for treatment of cancer (2022-06-21),
12. 11357779 - G1T38 superior dosage regimes (2022-06-14),
13. 11090306 - Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors (2021-08-17),
14. 11040042 - Transient protection of normal cells during chemotherapy (2021-06-22),
15. 10988479 - Morphic forms of trilaciclib and methods of manufacture thereof (2021-04-27),
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapies to address significant unmet needs in the treatment of cancer. G1’s pipeline includes three novel clinical-stage assets designed to address the limitations of widely used cancer therapies and improve outcomes for patients. G1 has a strong balance sheet and is well-positioned to advance its pipeline of potential best-in-class therapies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
48 Patents

#10 in Research Triangle Park, NC

#169 in North Carolina

#7,027 in US

#14,127 in the World

...
Research Triangle Park, NC, United States of America

G1 Therapeutics, Inc.

Forward Citations = 576

31 inventors:

goldMedal Jay Copeland Strum (41 out of 53 patents)

silverMedal Francis Xavier Tavares (28 out of 47 patents)

bronzeMedal Patrick Joseph Roberts (18 out of 24 patents)

4.  John Emerson Bisi (18 out of 23 patents)

5.  Hannah S White (7 out of 12 patents)

Please report any incorrect information to support@idiyas.com
Loading…